Cloudbreak Pharma shares halted amid probe into ‘IPO rigging’
Just 14 months after its market debut, the drug developer is under investigation over regulatory concerns that its IPO demand was artificially inflated Key Takeaways: Cloudbreak’s IPO drew strong retail…
Is the SFC punching hard enough to clamp down on market misconduct?
Hong Kong’s securities regulator has reportedly stepped up its use of criminal proceedings to deter market misconduct in years By A. Au Hong Kong’s Securities and Futures Commission (SFC)…
RELATED ARTICLES
-
Cold-chain provider Shanghai Shengsheng joins pharma IPO hopefuls
- Investors pile onto TenNor IPO with hopes for new type of gastric drug
-
Montage forecasts strong profit growth as shares plunge on Korea probe
688008.SHG
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE
- Insilico revenue soars above $100 million on AI drug partnerships
- A healthy return: drug spin-off nets Keymed up to $320 million
